Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Michigan Medical School
Ann Arbor, Estados UnidosPublicacións en colaboración con investigadores/as de University of Michigan Medical School (26)
2024
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
The Lancet Oncology, Vol. 25, Núm. 5, pp. 668-682
-
Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism
Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246
-
Recommendations for quantitative cerebral perfusion MRI using multi-timepoint arterial spin labeling: Acquisition, quantification, and clinical applications
Magnetic Resonance in Medicine, Vol. 92, Núm. 2, pp. 469-495
-
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma
Nature Communications, Vol. 15, Núm. 1
-
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8
2022
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)
Nature Medicine
-
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential
British Journal of Cancer, Vol. 126, Núm. 11, pp. 1595-1603
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Nature Medicine, Vol. 28, Núm. 3, pp. 557-567
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Hematopoiesis under telomere attrition at the single-cell resolution
Nature Communications, Vol. 12, Núm. 1
-
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
Journal of Clinical Oncology, Vol. 39, Núm. 25, pp. 2779-2790
2020
-
Mortality prediction in chronic obstructive pulmonary disease comparing the gold 2015 and gold 2019 staging: A pooled analysis of individual patient data
ERJ Open Research, Vol. 6, Núm. 4, pp. 1-10
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502
2016
-
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
The Lancet Oncology, Vol. 17, Núm. 4, pp. 484-495
-
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477
2015
-
Characterization of large structural genetic mosaicism in human autosomes
American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497
-
Consensus nomenclature for CD8+ T cell phenotypes in cancer
OncoImmunology, Vol. 4, Núm. 4